TY - JOUR
T1 - Pink1-deficiency in mice impairs gait, olfaction and serotonergic innervation of the olfactory bulb
AU - Glasl, Lisa
AU - Kloos, Karina
AU - Giesert, Florian
AU - Roethig, Anne
AU - Di Benedetto, Barbara
AU - Kühn, Ralf
AU - Zhang, Jingzhong
AU - Hafen, Ulrich
AU - Zerle, Julia
AU - Hofmann, Andreas
AU - Hrabé de Angelis, Martin
AU - Winklhofer, Konstanze F.
AU - Hölter, Sabine M.
AU - Vogt Weisenhorn, Daniela M.
AU - Wurst, Wolfgang
N1 - Funding Information:
We thank Bettina Sperling, Annerose Kurz-Drexler and Miriam Homburg for expert technical assistance and the animal care takers Rosina Pfeiffer and Carmen Haas. We also thank Dr. Lillian Garrett for critically reading the manuscript. This work was supported by the Deutsche Forschungsgemeinschaft ( SFB596 to KFW), the Federal Ministry of Education and Research (National Genome Research Network, 01GS08174 and 01GS0850 to WW), the Helmholtz Association (Virtual Institute of Neurodegeneration and the Helmholtz Alliance “Mental Health in an Ageing Society” (HelMA)), and the European Commission (EUMODIC: LSHG-2006-037188 ).
PY - 2012/5
Y1 - 2012/5
N2 - Parkinson's Disease (PD) is the most common neurodegenerative movement disorder. Autosomal-recessive mutations in the mitochondrial protein kinase PINK1 (PTEN-induced kinase 1) account for 1-2% of the hereditary early-onset cases. To study the mechanisms underlying disease development, we generated Pink1-deficient mice. In analogy to other genetic loss-of-function mouse models, Pink1-/- mice did not show morphological alterations in the dopaminergic system. As a consequence, no gross motor dysfunctions were observed indicating that these mice do not develop the cardinal symptoms of PD. Nonetheless, symptoms which develop mainly before bradykinesia, rigidity and resting tremor were clearly evident in Pink1-deficient mice. These symptoms were gait alterations and olfactory dysfunctions. Remarkably in the glomerular layer of the olfactory bulb the density of serotonergic fibers was significantly reduced. Concerning mitochondrial morphology, neurons in Pink1-/- mice had less fragmented mitochondria. In contrast, upon acute knock-down of Pink1 increased mitochondrial fragmentation was observed in neuronal cultures. This fragmentation was, however, evened out within days. Taken together, we demonstrate that Pink1-deficient mice exhibit behavioral symptoms of early phases of PD and present systematic experimental evidence for compensation of Pink1-deficiency at the cellular level. Thus, Pink1-deficient mice represent a model for the early phases of PD in which compensation may still impede the onset of neurodegeneration. Consequently, these mice are a valuable tool for studying Pink1-related PD development, as well as for searching for reliable PD biomarkers.
AB - Parkinson's Disease (PD) is the most common neurodegenerative movement disorder. Autosomal-recessive mutations in the mitochondrial protein kinase PINK1 (PTEN-induced kinase 1) account for 1-2% of the hereditary early-onset cases. To study the mechanisms underlying disease development, we generated Pink1-deficient mice. In analogy to other genetic loss-of-function mouse models, Pink1-/- mice did not show morphological alterations in the dopaminergic system. As a consequence, no gross motor dysfunctions were observed indicating that these mice do not develop the cardinal symptoms of PD. Nonetheless, symptoms which develop mainly before bradykinesia, rigidity and resting tremor were clearly evident in Pink1-deficient mice. These symptoms were gait alterations and olfactory dysfunctions. Remarkably in the glomerular layer of the olfactory bulb the density of serotonergic fibers was significantly reduced. Concerning mitochondrial morphology, neurons in Pink1-/- mice had less fragmented mitochondria. In contrast, upon acute knock-down of Pink1 increased mitochondrial fragmentation was observed in neuronal cultures. This fragmentation was, however, evened out within days. Taken together, we demonstrate that Pink1-deficient mice exhibit behavioral symptoms of early phases of PD and present systematic experimental evidence for compensation of Pink1-deficiency at the cellular level. Thus, Pink1-deficient mice represent a model for the early phases of PD in which compensation may still impede the onset of neurodegeneration. Consequently, these mice are a valuable tool for studying Pink1-related PD development, as well as for searching for reliable PD biomarkers.
KW - Compensation
KW - Early-onset Parkinson's Disease
KW - Gait impairment
KW - Genetic mouse model
KW - Mitochondrial dysfunction
KW - Olfactory dysfunction
UR - http://www.scopus.com/inward/record.url?scp=84862777779&partnerID=8YFLogxK
U2 - 10.1016/j.expneurol.2012.01.002
DO - 10.1016/j.expneurol.2012.01.002
M3 - Article
C2 - 22265660
AN - SCOPUS:84862777779
SN - 0014-4886
VL - 235
SP - 214
EP - 227
JO - Experimental Neurology
JF - Experimental Neurology
IS - 1
ER -